Hainan Longevity
Guides & research · Is stem cell therapy safe?

Is stem cell therapy safe? Risks, side effects and the screening that decides

Safer than its reputation in the trial literature, more dangerous than its advertising in the grey market — and the difference is almost never the cells. It is where they were made, how they were given, and who was allowed to have them.

The short answer

Stem cell therapy, as it is tested in registered clinical trials, has a good safety record: the most consistent side effect is a transient fever, and the large pooled analyses have not found an excess of infection, blood clots, cancer or death. Stem cell therapy as it is sold by an unlicensed clinic has a documented record of blindness, bacterial infection and bone growing where bone should not be. Those are not two verdicts on one therapy. They are two different products that share a name.

So “is stem cell therapy safe?” is really four questions. What cells, made where, released against what tests? Given by which route, at what dose, with what monitoring? To whom — and who was turned away? And what happens in the weeks after, at home? A program that answers all four in writing is as safe as clinical-stage medicine gets.

One boundary belongs at the top. This guide is about safety. Whether a program is lawful — the 2015 research-only rules, State Council Order No. 818 in force since 1 May 2026, what the Boao Lecheng zone licenses — is a separate question with its own guide: Is stem cell therapy legal in China? →

What the trial evidence says about stem cell therapy safety

Most licensed stem cell treatment for disease uses mesenchymal stem (or stromal) cells — MSCs — expanded from umbilical-cord tissue, bone marrow or fat, and given by intravenous infusion or injection into a joint. They are the best-studied cell product in the field, so the safety picture is unusually clear.

The first systematic review, published in PLoS ONE in 2012, pooled thirty-six studies and just over a thousand participants and found one significant association: transient fever. No link to infection, organ toxicity, malignancy or death. An updated meta-analysis in EClinicalMedicine in 2020 widened that to fifty-five randomised controlled trials and 2,696 patients receiving intravascular MSCs across heart disease, neurological, liver, lung and immune conditions. Fever again; no association with non-fever infusion reactions, infection, thrombotic or embolic events, malignancy, or death, with follow-up in some trials running to several years.

Two cautions keep that honest. These are trial patients — screened, infused in hospitals, followed on a schedule; the data say nothing about an untested product injected in a clinic with no crash cart. And “no signal in 2,696 patients” is not “no risk”; rare events need larger numbers than any meta-analysis holds, which is why licensed programs must keep reporting outcomes after approval.

Stem cell therapy risks and side effects, by mechanism

The mechanism of each adverse event tells you which safeguard prevents it.

Fever and infusion reactions. The common one: a low-grade fever, chills, fatigue or headache in the twenty-four hours after an intravenous infusion, usually self-limiting — the immune system noticing a large number of cells arriving at once. Slower infusion, pre-medication where the protocol calls for it, and an observation window after the drip are the safeguards; a fever that persists beyond a day, or a high fever at any point, is assessed for infection rather than sent to bed.
Clotting. The serious one trial data have been reassuring about, and the one a careful program still designs around. Cultured MSCs express tissue factor, a protein that triggers coagulation on contact with blood — the instant blood-mediated inflammatory reaction. High doses, fast infusion, poor viability and a patient who already clots easily all push the wrong way. Licensed protocols answer with dose ceilings, viability thresholds at release, controlled infusion rates, screening for clotting disorders and, in some hospitals, an anticoagulant alongside the cells. This is the main reason a stem cell infusion belongs in a hospital ward rather than a spa.
Infection from a contaminated product. Not a property of stem cells; a property of whoever made them. In 2018 the US Centers for Disease Control reported twelve patients in three states hospitalised with bloodstream and joint infections after injections of unapproved umbilical-cord-blood-derived products, traced to contaminated vials from one distributor — a manufacturing failure caught after the fact instead of before. The safeguard is a licensed GMP facility and a release panel — sterility, endotoxin, mycoplasma — that a batch must pass before a vial leaves the building.
Tumour formation. The fear most people bring, and the one most worth un-tangling. The cells that form tumours readily are pluripotent cells — embryonic stem cells and induced pluripotent stem cells — which can grow into any tissue and, injected raw, into a teratoma. That is why they are never given as raw cells, and why products derived from them remain in clinical trials rather than licensed treatment. MSCs are not pluripotent; they do not form teratomas, and the pooled trial data show no excess of malignancy. The residual theoretical concern is that MSCs might support the growth of a cancer that is already present, which is why active or recent malignancy is a standard exclusion for MSC programs. Immune-cell programs — autologous NK cells, for example — are a different class with a different profile, used for patients who already have a cancer diagnosis, under their own criteria.
The wrong route. Cells behave according to where they are put. In 2015 three women with macular degeneration had fat-derived cells injected directly into both eyes at a Florida clinic; the outcome, published in the New England Journal of Medicine in 2017, was severe and permanent vision loss in all three. Elsewhere, cells injected cosmetically into a face grew bone fragments in an eyelid. Neither is a story about MSCs; both are stories about a route and a dose that no licensed indication would ever have approved. The safeguard is the indication itself — a named disease, a filed route, a filed dose — which is what a licence is.

Where the cells come from decides most of it

For allogeneic (donor) cells, safety is decided in the manufacturing suite months before you arrive. A licensed program’s umbilical-cord MSCs come from screened, consented, full-term births; the donor is tested for transmissible infections; the tissue is expanded in a GMP cleanroom to a defined passage number; and each batch is released only after it passes a panel — viability, identity by surface markers, sterility, endotoxin, mycoplasma — with a certificate you are entitled to see. A batch that fails any one test is destroyed. That certificate, with its batch number, is the most useful piece of paper in the process; a program that cannot produce one has told you what you need to know.

Autologous programs, which draw, expand and return your own cells, remove the donor question but not the manufacturing one: the release panel still applies. Our guide to UC-MSC treatment for liver cirrhosis walks through a licensed allogeneic course; the NK cell guide an autologous one.

Who is declined, and why that protects you

Every licensed program carries written inclusion and exclusion criteria, and the exclusions are the safety system in its most concrete form. The classes recur across MSC programs everywhere: an active or recent cancer; an uncontrolled infection; a bleeding or clotting disorder; pregnancy or breastfeeding; a recent heart attack or stroke; organ failure beyond the point where the underlying condition could plausibly respond; and a poor performance status. The precise thresholds are the hospital’s — the fifteen exclusions for the cirrhosis program and the filed NK criteria are two worked examples — and they are applied by the treating hospital’s specialist panel from your own diagnostics, not by a salesperson from a form.

Being declined feels like a door closing. It is the opposite: a therapy that accepts everyone who can pay has no criteria, and a therapy with no criteria has no safety data that applies to you.

What “safe as delivered” looks like at a licensed hospital

The setting is the rest of the answer. In the zone, cell therapy is delivered as disease treatment inside licensed tertiary hospitals — intensive care on site, and the monitoring a ward provides: vital signs through the infusion, an observation window after it, a written pathway for an adverse event that names who is called and what is done. Outcomes are reported into the national real-world data program, mandatorily; that is what makes a licensed program clinical-stage rather than merely experimental, and it is how a rare event anywhere becomes a protocol change everywhere. How the zone is built for this →

One line from the retreat’s own rules belongs here. Stem cell programs are currently paused for longevity-only use: a guest who is well and simply wants an infusion will not receive one. If the precision assessment finds a condition on a licensed indication, or a guest arrives with a diagnosis or prescription from their own physician, the hospital’s panel considers them as it would any patient and stem cell therapy proceeds if the criteria are met. That is the exclusion criterion “no indication” applied before the first conversation. What happens on a longevity retreat, day by day →

Is the rest of the retreat safe?

The wellness retreat itself is diagnostics, specialist consultation and a written plan — a hospital-grade health check with a villa attached — and its risks are those of any thorough medical assessment. The partner hospitals also run non-stem-cell longevity programs, with no cell-therapy restriction and generally milder risk profiles. Therapeutic plasma exchange (TPE) needs good venous access and most often brings tingling around the mouth or fingers from the citrate anticoagulant, occasionally a drop in blood pressure; a nurse is at the bedside throughout. Hyperbaric oxygen (HBOT) most commonly causes ear discomfort from pressure change, and an untreated collapsed lung is an absolute bar to the chamber. NAD+ and other infusions can cause flushing or nausea if run too fast, which is why the rate is slow and supervised. Whole-body hyperthermia asks a cardiovascular question of every candidate first. Each program has its own screen, and each is delivered in the hospital, not the villa.

Six safety questions to ask any stem cell program

The legality guide gives six questions that separate a licensed program from a clinic advertisement. These six are the ones a physician at home would ask on your behalf.

1. May I see the batch release certificate? Viability, identity, sterility, endotoxin, mycoplasma, a batch number and a date — the certificate for your batch, not a brochure about the laboratory.
2. What is the route, the dose, and why? A licensed indication has a filed route and dose. “We tailor it to you” is an answer to a different question.
3. Who monitors me, where, and for how long after? A ward, a nurse, an observation window, and a named clinician who is called if something changes.
4. What would make you decline me? A program with criteria can list its exclusions from memory. A program without them will change the subject.
5. What happens if I have a fever at home in week two? A written aftercare plan with a contact, a threshold, and an instruction to see a local physician — in English.
6. Where does my outcome get reported? In the zone, into the real-world data program, mandatorily. Anywhere, at least to your own doctor, in a record you keep.
Bring your own physician into this early. A licensed program is an adjunct to the plan your specialists have set, never a replacement for it — and the paperwork above is what they will ask to see.

Frequently asked

Is stem cell therapy safe? In registered clinical trials, mesenchymal stem cell therapy has a consistently good safety record: pooled analyses of more than fifty randomised trials found transient fever as the main side effect and no excess of infection, blood clots, cancer or death. The serious harms on record — blindness, bacterial infections, ectopic bone — came from unlicensed clinics using untested products by unapproved routes. Safety is decided by manufacturing, route, dose, screening and setting.
What are the side effects of stem cell therapy? Most often a low-grade fever, chills or fatigue in the day after an intravenous infusion, usually self-limiting; injection into a joint can cause temporary pain and swelling. Rarer risks are infusion reactions and clotting, managed with dose limits, controlled infusion rates and screening. Infection is a risk of contaminated product, not of the cells, and is prevented by GMP manufacturing and sterility testing before release.
Can stem cell therapy cause cancer? Pluripotent cells — embryonic and induced pluripotent stem cells — can form teratomas and are not used as licensed treatment on the mainland. Mesenchymal stem cells are not pluripotent, do not form teratomas, and have shown no excess of malignancy in pooled trial data. Because they might in theory support an existing tumour, active or recent cancer is a standard exclusion for MSC programs.
Is stem cell therapy in China safe? Licensed stem cell therapy in China is delivered as disease treatment inside tertiary hospitals, with GMP-manufactured, release-tested cells, written inclusion and exclusion criteria and mandatory outcome reporting — the strongest safety frame available outside a formal trial. Stem cell “treatment” sold by a clinic, beauty salon or cell company outside that frame is both unlawful under Order 818 and unsafe for the reasons above. Legal and safe are different questions; both have to be answered yes.
Is stem cell therapy safe for anti-ageing? There is no licensed anti-ageing indication on the mainland, so the question cannot be answered from any licensed program’s data. At the retreat, stem cell programs are paused for longevity-only use; they proceed only for a diagnosed condition on a licensed indication, whether found at the check-up or brought as a prescription. Longevity programs here are built on diagnostics, wellness and the non-cell programs.
Who should not have stem cell therapy? The recurring exclusions are an active or recent cancer, an uncontrolled infection, a bleeding or clotting disorder, pregnancy or breastfeeding, a recent heart attack or stroke, advanced organ failure and a poor performance status. The exact thresholds are set by the treating hospital’s filed criteria and applied by its specialist panel from your own diagnostics; some guests are declined.
Write to us →Tell us where you’re starting from — a care manager replies within one working day.

Or download the Retreat Dossier (PDF) → — itinerary, inclusions, programs, practicalities.